{"id":178,"date":"2025-03-27T10:00:00","date_gmt":"2025-03-27T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=178"},"modified":"2025-09-03T03:52:34","modified_gmt":"2025-09-03T03:52:34","slug":"china-bd-2025-puhe-biopharma-and-astrazeneca-enters-a-2-billion-usd-license-on-prmt5i-ph020-bay-3713372","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/178.html","title":{"rendered":"[China BD 2025] Puhe BioPharma and AstraZeneca enters a 2 billion USD license on PRMT5i PH020 (BAY 3713372)"},"content":{"rendered":"\n<p>Announced Date: 2025-03-26 (March 26, 2025)<\/p>\n\n\n\n<p>Asset Name: PH020 (BAY 3713372)<\/p>\n\n\n\n<p>Licensor: Suzhou\u00a0Puhe BioPharma  (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Bayer\uff08DE\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small \u00a0Molecule, Oral<\/p>\n\n\n\n<p>Asset Target: PRMT5 (protein arginine methyltransferase 5) inhibitor<\/p>\n\n\n\n<p>Potential Indication: MTAP-deleted solid tumors<\/p>\n\n\n\n<p>Current Stage: Phase I clinical trial, global\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Undisclosed<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.bayer.com\/media\/en-us\/bayer-and-puhe-biopharma-enter-into-global-license-agreement-for-clinical-phase-i-prmt5-inhibitor\/\">Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-03-26 (March 26, 2025) Asset Name: PH020 (BAY 3713372) Licensor: Suzhou\u00a0Puhe BioPharma (China) Licensee &hellip; <a title=\"[China BD 2025] Puhe BioPharma and AstraZeneca enters a 2 billion USD license on PRMT5i PH020 (BAY 3713372)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/178.html\"><span class=\"screen-reader-text\">[China BD 2025] Puhe BioPharma and AstraZeneca enters a 2 billion USD license on PRMT5i PH020 (BAY 3713372)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-178","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=178"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/178\/revisions"}],"predecessor-version":[{"id":179,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/178\/revisions\/179"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}